

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jun 2026

A Comparative Study of the Effect of Two Concentrations of Dextrose Injection (12.5% And 25%) on Pain and Function of Patients with Rotator Cuff Tendinopathy of The Shoulder

Protocol summary

Study aim

Evaluation of the effect of injection of 12.5% and 25% dextrose prolotherapy under ultrasound guidance on pain and function in rotator cuff tendinopathy

Design

Semi-experimental clinical trial with control group, with parallel groups, unblinded, computerized randomization, phase 3 on 66 patients

Settings and conduct

Selection of participants from people who come to the sports medicine department of Imam Hospital due to shoulder pain First group: injection of 2 ml of 25% dextrose prolotherapy solution (containing 1 ml of 50% dextrose and 1 ml of 2% lidocaine) in the clinic Second group: injection of 2 ml of 12.5% Prolotherapy dextrose solution (containing 0.5 ml of 50% dextrose and 1.5 ml of 2% lidocaine) in the clinic Control group: home-based exercise therapy

Participants/Inclusion and exclusion criteria

Inclusion Criteria: Adults (over 20 years) Chronic shoulder pain for more than six months Shoulder ultrasound showing chronic tendinopathy of the supraspinatus tendon The average intensity of shoulder pain is more than 3 points on the ten-point Visual Analog Scale Exclusion Criteria: Associated with adhesive capsulitis Shoulder joint replacement Shoulder surgery or arthroscopy of the injured shoulder within the past year Any kind of injection in the shoulder joint within the last three months. Neurological disease that causes weakness on the affected side Impaired cognitive function

Intervention groups

First group: injection of 2 ml of 25% dextrose prolotherapy solution (containing 1 ml of 50% dextrose and 1 ml of 2% lidocaine) Second group: injection of 2 ml of 12.5% Prolotherapy dextrose solution (containing 0.5 ml of 50% dextrose and 1.5 ml of 2% lidocaine) Control

group: exercise therapy

Main outcome variables

Primary outcome: mean score in shoulder pain and disability index Secondary outcomes: shoulder active range of motion, supraspinatus tendon thickness

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20230821059204N2**
Registration date: **2023-10-12, 1402/07/20**
Registration timing: **prospective**

Last update: **2023-10-12, 1402/07/20**

Update count: **0**

Registration date

2023-10-12, 1402/07/20

Registrant information

Name

Hanieh Ahmadi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 11 3336 6552

Email address

h.ahmadi@mazums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-10-22, 1402/07/30

Expected recruitment end date

2024-03-19, 1402/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

A Comparative Study of the Effect of Two Concentrations of Dextrose Injection (12.5% And 25%) on Pain and Function of Patients with Rotator Cuff Tendinopathy of The Shoulder

Public title

Effect of Dextrose Injection in Rotator Cuff Tendinopathy of The Shoulder

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Adults (over 20 years) Chronic shoulder pain for more than six months Shoulder ultrasound of the supraspinatus tendon showing chronic tendinopathy such as a tear or tendinosis The average intensity of shoulder pain is more than 3 points on the ten-point Visual Analog Scale (VAS) Agreeing and complying with our study protocol The possibility of signing an informed consent form

Exclusion criteria:

Associated with adhesive capsulitis and limited range of motion of the shoulder Shoulder joint replacement Shoulder surgery or arthroscopy of the injured shoulder within the past year Injection of steroid, hyaluronic acid or platelet-rich plasma or any type of prolotherapy injection in the shoulder joint within the last three months Neurological disease that causes weakness on the affected side Impaired cognitive function and inability to complete the questionnaire Concurrent participation in another clinical trial

Age

From **20 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **66**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization will be done using computer generated random numbers. Based on the selected numbers, the participants will be assigned to a 12.5% hypertonic dextrose prolotherapy group, another 25% hypertonic dextrose prolotherapy group, and a control group of exercise therapy.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features

In the first group, 2 ml of 25% dextrose Prolotherapy solution (containing 1 ml of 50% dextrose and 1 ml of 2% lidocaine) and in the second group 2 ml of 12.5% dextrose Prolotherapy solution (containing 0.5 ml of 50% dextrose and 1.5 ml of 2% lidocaine) will be injected. The control group will be exercise therapy.

Secondary Ids

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Mazandaran University of Medical Sciences, Imam Hospital

Street address

Serah Joibar, the beginning of Vali Asr Highway, the headquarters of Mazandaran University of Medical Sciences and Health Services

City

Sari

Province

Mazandaran

Postal code

3397148157

Approval date

2023-04-19, 1402/01/30

Ethics committee reference number

IR.MAZUMS.IMAMHOSPITAL.REC.1402.14941

Health conditions studied**1****Description of health condition studied**

Rotator cuff tendinopathy of the shoulder

ICD-10 code

S46.0

ICD-10 code description

Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder

Primary outcomes**1****Description**

Average score in the Shoulder Pain and Disability Index (SPADI) of the injured shoulder

Timepoint

At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention

Method of measurement

The Shoulder Pain and Disability Index (SPADI) is a self-administered assessment tool used to measure shoulder pain and disability. It has five pain items and eight disability items measured on the Visual Analogue Score. Pain and disability subscales are calculated as the mean of the corresponding items on a 0-100 scale, with the highest score indicating the most severe pain and disability. In this study, the total outcome score used for statistical analysis will be calculated as the sum of pain and disability subscales.

Secondary outcomes

1

Description

Active range of motion of the shoulder

Timepoint

At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention

Method of measurement

Active shoulder range of motion, i.e., forward flexion, internal rotation, external rotation, and abduction in standing position, will be assessed using a goniometer. Patients will move their shoulders slowly until they reach an angle at which pain is felt, and this movement will be performed three times to record the average value of the angle.

2

Description

Supraspinatus tendon thickness

Timepoint

At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention

Method of measurement

Using ultrasound, the maximum thickness of the supraspinatus tendon will be measured in millimeters.

Intervention groups

1

Description

Intervention group 1: The injection will be performed under ultrasound guide by a sports medicine specialist. Patients will maintain an upright sitting position with shoulder extension, arm flexion, and hand to hip touch to obtain a longitudinal view of the supraspinatus tendon. A prolotherapy injection session will be performed under ultrasound guide in aseptic conditions using a 23-G needle to the insertion site of the supraspinatus tendon. In the first group, 2 ml of 25% Prolotherapy dextrose solution (containing 1 ml of 50% dextrose and 1 ml of 2% lidocaine) will be injected.

Category

Treatment - Drugs

2

Description

Intervention group 2: The injection will be performed under ultrasound guide by a sports medicine specialist. Patients will maintain an upright sitting position with shoulder extension, arm flexion, and hand to hip touch to obtain a longitudinal view of the supraspinatus tendon. A prolotherapy injection session will be performed under ultrasound guide in aseptic conditions using a 23-G needle to the insertion site of the supraspinatus tendon. In the first group, 2 ml of 12.5% Prolotherapy dextrose solution (containing 0.5 ml of 50% dextrose and 1.5 ml of 2% lidocaine) will be injected.

Category

Treatment - Drugs

3

Description

Control group: The control group will be given exercise therapy, which exercises will be given to the patient in a booklet, and they will be taught in each visit that the exercises in the first week include correcting the position of the scapula and the shrug of the scapula; in the second week includes external rotation at zero degrees; in the third week, it includes internal rotation at 0 degrees, and in the fourth week, it includes boat movement at 45 degrees, boat movement at 90 degrees, anterior shoulder stretching and trunk stretching in a sitting position.

Category

Treatment - Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Department of Sports Medicine, Mostafavian Clinic, Sari Imam Khomeini Hospital

Full name of responsible person

Hanieh Ahmadi

Street address

Sports Medicine Department, Mostafavian Clinic, Razi No. 3 Alley, Razi St., Sari

City

Sari

Province

Mazandaran

Postal code

4816868890

Phone

+98 11 3336 6552

Email

h.ahmadi@mazums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Mazandaran University of Medical Sciences

Full name of responsible person

Pedram Ebrahimnejad

Street address

Department of pharmaceuticals, Faculty of Pharmacy,
Mazandaran University of Medical Sciences

City

Sari

Province

Mazandaran

Postal code

4847193697

Phone

+98 11 3354 3081

Email

pebrahimnejad@mazums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Mazandaran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries

Contact**Name of organization / entity**

Mazandaran University of Medical Sciences

Full name of responsible person

Hanieh Ahmadi

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Sport Medicine

Street address

Sports Medicine Department, Mostafavian Clinic, Razi
No. 3 Alley, Razi St.

City

Sari

Province

Mazandaran

Postal code

4816868890

Phone

+98 11 3336 6552

Fax**Email**

H.ahmadi@mazums.ac.ir

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Mazandaran University of Medical Sciences

Full name of responsible person

Hanieh Ahmadi

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Sport Medicine

Street address

Sports Medicine Department, Mostafavian Clinic, Razi
No. 3 Alley, Razi St.

City

Sari

Province

Mazandaran

Postal code

4816868890

Phone

+98 11 3336 6552

Fax**Email**

H.ahmadi@mazums.ac.ir

Person responsible for updating data

Contact**Name of organization / entity**

Mazandaran University of Medical Sciences

Full name of responsible person

Mina Ghaderi

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Sport Medicine

Street address

Sports Medicine Department, Mostafavian Clinic, Razi
No. 3 Alley, Razi St.

City

Sari

Province

Mazandaran

Postal code

4816868890

Phone

+98 11 3336 6552

Email

minaghaderi89@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available